Ignite Creation Date:
2025-12-24 @ 4:39 PM
Ignite Modification Date:
2026-05-05 @ 12:15 PM
Study NCT ID:
NCT05108766
Status:
COMPLETED
Last Update Posted:
2023-04-12
First Post:
2021-10-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis
Sponsor:
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
Tildra-PsO-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None